Issued by Novo Nordisk
For the 16th consecutive year, Novo Nordisk has published its integrated 2019 Annual report detailing the company’s year-end performance.
February 18, 2020 – For the 16th consecutive year, Novo Nordisk has published its integrated 2019 Annual report detailing the company’s year-end performance.
Still accounting for financial, social and environmental performance, the Management Review details the company’s progression in four new dimensions of strategic aspirations for 2025: purpose and sustainability; innovation and therapeutic focus; commercial execution; and financials.
The report has changed format and moved away from the magazine-style to pursue a simpler, smarter and more lean reporting. For the first time, the report is made in a digital-first HTML-version including Consolidated statements and notes, which can be viewed, bookmarked and shared across platforms.
Sales increased by 9% measured in Danish kroner and by 6% at CER to DKK 122,021 million in 2019.
Operating profit increased by 11% in Danish kroner and by 6% at CER to DKK 52,483 million, which is in line with the latest guidance for operating profit growth measured at CER of '4-6%' in 2019
In November 2019, Novo Nordisk introduced new strategic aspirations for 2025 in connection with its Capital Markets Day. The long-term financial targets were met with the full-year 2019 results.
In 2019, Novo Nordisk provided medical treatment to an estimated 30.0 million people with diabetes worldwide, compared with 29.2 in 2018. This 3% increase was primarily driven by sales of long-acting, premix and fast-acting insulins and GLP-1 products.
An estimated 2.9 million people were treated with insulin under Novo Nordisk’s Access to Insulin Commitment in 2019, of which approximately 200,000 people were reached through sales to humanitarian organisations. Under Access to Insulin Commitment, the company guarantees to provide low-priced human insulin to governments in the poorest parts of the world and selected humanitarian organisations at a ceiling price of USD 4 per vial.
In 2019, the average price the insulin was sold at equals USD 0.12 per patient per day. Beyond this commitment, Novo Nordisk sold human insulin at or below the ceiling price in other countries, reaching an estimated additional 2.2 million people in 2019.
In 2019, 76% of power for production sites was sourced from renewable energy.
In 2019, total emissions across operations and transportation was 306,000 tons CO2. Emissions are expected to decrease significantly in 2020 due to various renewable energy projects, including solar power across all US operations, wind power in Europe and green steam in Denmark.
The company’s target is to have zero emissions from operations and transportation by 2030.
For more information, please contact:
Charlotte Zarp Andersson
Senior Media Relations Manager
Tel.: +45 4442 7603
Link HTML report: https://annualreport2019.novonordisk.com/
Link to landing page: https://www.novonordisk.com/annualreport#
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. We believe that a healthy economy, environment and society are fundamental to long-term value creation. This is why we manage our business in accordance with the Triple Bottom Line business principle and consider the financial, environmental and social impact of our business decisions. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today's business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.
More from Novo Nordisk